Since the discovery of the role of DUX4 in FSHD pathology, the development of cell and animal models have been the center of attention to study the DUX4-mediated toxicity in FSHD muscles and more importantly to evaluate therapeutic and pharmaceutical strategies targeting DUX4. Here, DUX4 is linked to facioscapulohumeral muscular dystrophy.